Researcher Profile Form First National Pediatric Brain Tumor Research Meeting March 9, 2025 - Jerusalem
Researcher: Prof. Michal Besser
Current Role & Affiliation
Title/Position: Chief Technology Officer; Associate Professor
Institution: Davidoff Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center; Tel-Aviv University
Email: mbesser@tauex.tau.ac.il
Phone: 054-4222667
Prof. Besser serves as Chief Technology Officer at the Davidoff Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center, and as an Associate Professor at Tel-Aviv University.
Research Focus
● Immunology
● Cell therapy
● Process development for cell and gene therapies
Current Projects Related to Pediatric Brain Tumors
● Development of advanced cell therapies for pediatric cancer
● Process innovation for cellular infusion products
● Development of novel CAR T therapies
Laboratory/Research Resources
● Cell therapy manufacturing platforms
● Immunological research expertise
Collaboration Interests
● Cell and gene therapy advancements
● Early-stage innovation in immunotherapy
What You Can Offer Potential Collaborators
● Expertise in immunology and cell therapy
● Process development for IND submissions
Selected Publications
1. Lin CP et.al. Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness. Cancer Cell. 2024. 42(4):623-645.e10.
2. Itzhaki O. et.al. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. J Immunother Cancer. 2020; 8(1):e000148.
Keywords
Immunology, Cell Therapy, Gene Therapy, Process Development
Brief Bio
Prof. Michal Besser, is an expert in immunology, cell therapy and translational medicine with over 18 years of combined academic and industry experience. Prof. Besser is CTO, at the Davidoff Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center and Associate Professor at the Department of Clinical Immunology and Microbiology at Tel-Aviv University, Israel.
She completed her undergraduate studies and PhD at the Ludwig Maximillian University, Munich, Germany, and her postdoctoral research at the Weizmann Institute of Science, Rechovot, Israel. Prof. Besser has vast experience in early-stage innovation, process development, and IND submissions for a wide range of cell and gene therapies.
